Business Context and Reporting Period
Calidi Biotherapeutics, Inc. (CLDI), a Delaware corporation and emerging growth company, filed this Form 8-K on July 8, 2024, reporting events occurring on July 1, 2024. The company is headquartered in San Diego, California, and its securities trade on the NYSE American LLC.
Key Financial Metrics
This filing reports a specific financing transaction rather than periodic financial performance metrics such as revenue, profit, or operating cash flow. The key financial details disclosed are:
- Debt Instrument: Promissory Note issued to Dennis R. Conklin.
- Principal Amount: $600,000.
- Interest Rate: 15.0% per annum (simple interest).
- Disbursement Date: July 2, 2024.
- Maturity Date: Three years from the Payment Date (July 2, 2027), unless accelerated by default.
- Repayment Terms: Annual payments of accrued interest are required after each calendar year, with remaining interest and principal due at maturity.
Material Changes
The filing discloses the entry into a Material Definitive Agreement and the creation of a Direct Financial Obligation. There is no comparative data provided in this document to assess changes in revenue, margins, or liquidity versus prior periods, as this is a current report of a specific event rather than a periodic financial statement.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or a discussion of general business risks. The primary contingency noted is the potential for the debt to become due earlier than the maturity date in the event of a default under the terms of the Note.
Investor Verification Checklist
- Verify the full text of the Loan Agreement (Exhibit 10.1) and Promissory Note (Exhibit 10.2) for specific default triggers and covenants.
- Confirm the impact of the 15.0% interest rate on the company's future cash flow requirements.
- Review the company's most recent 10-Q or 10-K to assess current liquidity levels relative to this new $600,000 obligation.
- Check for any subsequent filings regarding the actual receipt of funds on July 2, 2024.